Atomo Diagnostics Issues New Shares and Lodges Cleansing Notice to Support Trading

Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.

Atomo Diagnostics has issued 90,909,091 new fully paid ordinary shares at $0.033 each to new and existing professional, sophisticated and other exempt investors, in line with a previously announced capital raising. The shares were issued without a prospectus under the Corporations Act disclosure exemptions, with the company confirming ongoing compliance with its financial reporting and continuous disclosure obligations, and stating there is no excluded information requiring disclosure, thereby facilitating secondary trading of the new securities within the regulatory framework.

Atomo’s confirmation via a cleansing notice under Section 708A supports liquidity for investors in the newly issued stock while signalling that its governance and reporting remain in good standing. The placement strengthens the company’s capital base as it continues to commercialise its rapid diagnostic technologies across global markets, potentially underpinning future operational execution and expansion in its core infectious disease and women’s health testing segments.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies integrated rapid diagnostic test devices to the global diagnostics market. Its patented point-of-care and at-home testing platforms are commercialised internationally for applications including COVID-19, HIV, viral versus bacterial differentiation and female health, supported by existing supply agreements.

Average Trading Volume: 2,045,256

Technical Sentiment Signal: Sell

Current Market Cap: A$25.93M

See more data about AT1 stock on TipRanks’ Stock Analysis page.